MA-EXAGRID
ExaGrid ® , a leading provider of intelligent hyperconverged storage for backup with data deduplication, today announced record bookings and revenue for Q4-2019 ending in December as well as a record fiscal year 2019. ExaGrid had significant growth in the Americas, Latin America, EMEA and APAC.
“This was our best quarter and fiscal year for bookings and revenue to date,” said Bill Andrews, CEO and President of ExaGrid. “We added over 100 new customers with a record number of new customer six-figure purchase orders. We achieved double-digit growth over the same quarter a year ago. ExaGrid focuses on organizations that need to store hundreds of terabytes to petabytes of backup data.”
Partner and Product Highlights in Q4-2019
- ExaGrid continued its strong sales growth with mid-market to enterprise organizations that use Veeam® Software, Commvault® , Veritas® NetBackup, Oracle RMAN Direct and other enterprise backup applications.
- ExaGrid had a record quarter for backup storage behind Commvault® due in part to an announcement made earlier in the year about ExaGrid’s ability to further deduplicate Commvault deduplicated data . ExaGrid does not require any change to the Commvault configuration and can improve backup efficiency by a factor of 3X.
- ExaGrid announced a new data storage solution for Acronis® Cyber Backup which provides efficient edge data protection and storage for remote sites.
- ExaGrid was voted “Backup Storage Innovation of the Year ” at Storage, Digitalisation + Cloud (SDC) Awards 2019.
ExaGrid solves the three inherent compute problems to achieve faster backups, restores, and VM boots by leveraging its unique Landing Zone, adaptive deduplication, and scale-out architecture.
“First-generation deduplication solutions can be cost prohibitive for backup storage and are slow for backups, restores, and VM boots, which is why a high percentage of ExaGrid’s newly-acquired customers are replacing Dell EMC Data Domain, HPE StoreOnce, and the Veritas NetBackup 5200/5300 series of appliances. We are replacing low cost primary storage disk behind Commvault, as ExaGrid is far less expensive than Dell, HPE Nimble, NTAP eSeries and Cisco 3260, when customers require longer term retention,” Andrews said. “We continue to see growth behind Commvault, Veeam and Veritas NetBackup as the company moves up market.”
All backup storage vendors reduce storage and bandwidth to varying degrees, but most provide slow ingest rates due to deduplication being performed ‘inline.’ Additionally, other solutions only store deduplicated data, which causes restore speeds and VM boots to be very slow. ExaGrid’s ingest rate is 6X faster than its closest competitor. Unlike the first-generation vendors that only add capacity as data grows, ExaGrid appliances add compute with capacity, ensuring that the backup window remains fixed in length. Only ExaGrid uses a scale-out architecture with a unique Landing Zone, which holistically addresses all of the scalability and performance challenges of backup storage.
ExaGrid’s turnkey disk-based backup system combines enterprise storage with zone-level data deduplication, delivering a disk-based solution that is far more cost effective than low cost disk. Unlike first-generation inline/scale-up deduplication solutions that were either built into a backup application media server or into a dedicated storage appliance, ExaGrid delivers the backup industry’s only true Landing Zone and scale-out architecture with data deduplication. Utilizing ExaGrid’s Landing Zone with adaptive deduplication typically halves the cost of the first-generation large brand solutions and is 3X the backup performance and 20X the restore/VM boot performance. By using a scale-out architecture, ExaGrid is the only solution that keeps the backup window fixed in length as data grows and eliminates both forklift upgrades and forced product obsolescence.
About ExaGrid
ExaGrid provides intelligent hyperconverged
storage for backup with data deduplication, a unique Landing Zone, and
scale-out architecture. ExaGrid’s Landing Zone provides for the fastest
backups, restores, and instant VM recoveries. Its scale-out architecture
includes full appliances in a scale-out system and ensures a
fixed-length backup window as data grows, eliminating expensive forklift
upgrades. Visit us at exagrid.com
or
connect with us on LinkedIn
.
See what our customers have to say about their own ExaGrid experiences
and why they now spend significantly less time on backup in our customer
success stories
.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005250/en/
Contact:
Media Contact: Stacey Foster ExaGrid sfoster@exagrid.com 508-898-2872 x0248
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
